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Objective. To determine the ability of drugs that activate inhibitory G protein-coupled receptors (GPCRs) expressed in peripheral voltage-gated sodium channel 1.8 (Na V 1.8)-positive sensory neurons to control osteoarthritis (OA)-associated pain.
Methods. We used designer receptors exclusively activated by a designer drug (DREADD) technology, which employs engineered GPCRs to activate or inhibit neurons upon binding the synthetic ligand clozapine Noxide (CNO). Na V 1.8-Pdi C57BL/6 mice were generated to express the inhibitory DREADD receptor Pdi in Na V 1.8-expressing sensory neurons. Destabilization of the medial meniscus (DMM) surgery was performed in 10-week-old male mice. Four, 8, 12 , or 16 weeks after surgery, knee hyperalgesia or hind paw mechanical allodynia was tested. Subsequently, CNO or vehicle was administered, and the effect on pain-related behaviors was measured by a blinded observer. Morphine was used as a control.
Results. Immunohistochemistry and electrophysiology confirmed functional expression of the inhibitory DREADD receptor Pdi by Na V 1.8-positive sensory neurons. Acute inhibition of Na V 1.8-expressing neurons in mice treated with CNO reduced knee hyperalgesia 4 weeks after DMM surgery and reduced mechanical allodynia 8 weeks after DMM surgery. Inhibition had no effect on pain-related behaviors 12 and 16 weeks after DMM surgery. Morphine, a drug that activates GPCRs in the peripheral and central nervous systems, was still effective in the later stage of experimental OA.
Conclusion. Chemogenetic inhibition of Na V 1.8-expressing neurons blocks knee hyperalgesia and mechanical allodynia in early experimental OA, but is no longer efficacious in the later stages. These data indicate that activation of inhibitory GPCRs located solely outside the central nervous system may be ineffective in treating chronic OA pain.
Pain is one of the most debilitating symptoms associated with progressive osteoarthritis (OA), yet few options exist for efficacious treatment of chronic OA pain. Conventional treatment options for OA pain rely mainly on nonsteroidal antiinflammatory drugs (NSAIDs) (1, 2) , but these drugs are only moderately effective and are associated with serious long-term risks (3) . The development of more efficacious and safer pharmacologic therapies will depend on gaining a better understanding of the basic mechanisms that underlie OA pain.
G protein-coupled receptors (GPCRs) constitute one of the largest groups of drug targets, with an estimated 30-40% of approved drugs targeting these receptors (4) . Drugs such as opioids produce analgesic effects in a wide variety of circumstances by activating opioid receptors, which are GPCRs coupled to inhibitory G i/o proteins (5) . G i/o proteins then cause downstream signaling, resulting in reduced nerve excitability and inhibition of neurotransmission (5) . As such, opioids have been recommended as an alternative for treating OA pain when NSAIDs are ineffective (1, 2) . These and other inhibitory GPCRs, such as the cannabinoid receptors, are localized both peripherally on nociceptive neurons in the dorsal root ganglion (DRG) (6) and in the central nervous system (CNS), at several different levels of the neuraxis (5-7). Because the psychoactive, respiratory, and gastrointestinal side effects associated with many of the drugs that target inhibitory GPCRs are mediated by the CNS (5, (8) (9) (10) , there have been efforts to produce agonists that do not enter the CNS and that selectively activate peripheral receptors. Indeed, a recent study using a conditional knockout mouse approach supports this idea by demonstrating that removing peripheral neuron expression of the m-opioid receptor reduces, but does not abolish, the analgesic effectiveness of morphine in a model of inflammatory pain (11) . However, the effectiveness of peripheral activation of opioid, cannabinoid, or other novel inhibitory GPCR targets in the production of analgesia remains to be fully tested in the context of a specific disease (9, 12) .
A potentially important factor to be considered in the design of novel OA pain therapeutics is the long-term and variable nature of the disease. Pain experienced in association with OA has been characterized qualitatively and may be classified by 3 main stages (13) . In early OA, pain is associated with high-impact activity. As disease progresses, low-impact activities such as walking and climbing stairs become painful. Finally, late-stage OA is characterized by chronic pain accompanied by acute, unpredictable pain episodes (13) . This chronic OA pain differs from other types of chronic pain since the tissue injury never resolves (14) . It is unclear whether targeting inhibitory GPCRs solely localized in the periphery may be analgesic in these different stages.
The chronic disease course of OA can be recapitulated in mice by surgical destabilization of the medial meniscus (DMM) (15) , which induces a mild instability in the knee and results in joint damage that develops slowly over the course of 16 weeks or longer (16) (17) (18) . By 2-4 weeks after DMM surgery, mild cartilage lesions, subchondral bone sclerosis, and osteophytes are evident (15, (19) (20) (21) , while synovitis has recently been reported to peak during this time as well (16) . As the disease progresses, cartilage lesions worsen, osteophytes mature, and synovitis resolves, but not completely (16, 22) . We and others have shown that mice develop pain-related behaviors associated with this progressive joint damage, with each behavior developing on a unique time course. Mechanical allodynia in the ipsilateral hind paw appears by week 4 after DMM (but not sham) surgery and is maintained through 16 weeks (17, (23) (24) (25) . Herein we describe another measure of sensitivity, hyperalgesia of the knee, which is more strongly associated with the early stage of disease prior to 8 weeks. Previous studies in other OA models have used vocalization in response to pressure applied to the knee by hand as a means of assessing knee hyperalgesia (26, 27) ; in the present study, we used a device previously validated in models of inflammatory arthritis (28, 29) to apply a range of forces to the knee in order to determine a quantitative withdrawal threshold. Decreases in locomotive behaviors (distance traveled, climbing, rearing) (17, 30) , changes in gait (31) , and decreases in weight bearing on the operated limb (30) only develop with the onset of moderate-to-severe joint damage (.8 weeks after surgery).
One way of investigating whether inhibitory GPCRs on peripheral neurons can be targeted to modulate these pain-related behaviors at different stages of the DMM model is through chemogenetic procedures. The most widely used chemogenetic approach is a platform termed designer receptors exclusively activated by designer drugs (DREADD) (32) . DREADD technology uses engineered GPCRs to activate or inhibit neurons based on the binding of synthetic chemicals (for review, see ref. 33 ).
In the present study, we used a neuronal inhibitory DREADD based on an engineered M 4 muscarinic acetylcholine receptor, which exerts its effects through activation of the inhibitory G i/o protein pathway (32) . Activation of the engineered receptor (termed Pdi) with the synthetic chemical agonist clozapine N-oxide (CNO) has been shown to inhibit neuronal activity (34) , mimicking the actions of analgesics that target this inhibitory GPCR pathway. In order to genetically target expression of this engineered Pdi receptor to the peripheral nervous system, we used voltage-gated sodium channel 1.8 (Na V 1.8) as a marker, since this channel is expressed by a large subset of sensory neurons in the DRG (35) . Approximately 75% of DRG sensory neurons have been shown to express Na V 1.8, which includes .90% of C-fiber nociceptors (pain-sensing neurons) and C-fiber low-threshold mechanoreceptors, as well as a lower percentage of Adfiber nociceptors and Ab-fiber afferents (35) . Previous studies in experimental models of OA have shown the Na V 1.8 channel itself to be important for the transmission of nociceptive information at both the peripheral (36) and central (37) levels.
The overall aim of this study was to examine the analgesic effects of peripheral activation of inhibitory GPCRs on pain-related behaviors at different stages after DMM surgery, using novel Na V 1.8-Pdi mice. We focused on two pain-related behaviors, knee hyperalgesia and mechanical allodynia in the hind paw. Findings were compared to analgesia produced by morphine, a commonly used opioid for pain management, which exerts its effects through activation of inhibitory GPCRs in both the peripheral nervous system and CNS (5). (34) . Dr. Dymecki's laboratory has previously characterized these mice and verified that CNO suppressed action potential firing in neurons expressing Pdi (34) . Na V 1.8-Cre or Na V 1.8-Cre-TdTomato mice were crossed with Pdi mice in order to generate Na V 1.8-Pdi or Na V 1.8-TdTomato-Pdi mice. All experiments used mice heterogeneous for both Na V 1.8 and Pdi. Surgery. DMM surgery was performed in the right knee of 10-week-old male mice (25-30 gm) under isoflurane anesthesia, as previously described (15, 17) . Briefly, after medial parapatellar arthrotomy, the anterior fat pad was dissected to expose the anterior medial meniscotibial ligament, which was severed. The knee was flushed with saline and the incision was closed. Sham surgery followed the same procedure to expose the anterior medial meniscotibial ligament, but the ligament was left intact. Mice were not administered analgesia after surgery.
MATERIALS AND METHODS
Knee hyperalgesia. Knee hyperalgesia was measured using a Pressure Application Measurement (PAM) device (Ugo Basile) by adapting the methods previously established by Barton et al (28) and Leuchtweis et al (29) . Mice were manually restrained, and the hind paw was lightly pinned with a finger in order to hold the knee in flexion at a similar angle for each mouse. With the knee in flexion, the PAM transducer was pressed against the medial side of the ipsilateral knee while the operator's thumb lightly held the lateral side of the knee. The PAM software guided the user to apply an increasing amount of force at a constant rate (30 gm/second), up to a maximum of 450 gm. If the mouse tried to withdraw its knee, the force at which this occurred was recorded. If the mouse did not try to withdraw, the maximum possible force of 450 gm was assigned. Two measurements were obtained per knee, and the withdrawal force data were averaged. Knee hyperalgesia was assessed before surgery and at weeks 2, 4, 8, 12, and 16 after sham surgery (n 5 6-7 mice per time point) or DMM surgery (n 5 6-8 mice per time point) in wild-type (WT) mice. Four weeks after DMM surgery, a second set of WT mice was tested using morphine (10 mg/kg using 10 mg/ml morphine in saline, subcutaneously [SC]) (Rush University pharmacy) (n 5 4) or vehicle (saline) (n 5 5) to establish that knee hyperalgesia was a pain-related behavior. Finally, knee hyperalgesia was assessed before surgery and at weeks 4, 8, 12, and 16 after DMM surgery in Na V 1.8-Pdi mice. In all cases, the assessor (SI) was blinded to the experimental groups.
Mechanical allodynia. Na V 1.8-Pdi mice were tested for secondary mechanical allodynia of the ipsilateral hind paw using von Frey filaments and the up-down staircase method, as previously described (17) . Withdrawal thresholds were assessed before surgery and weeks 4, 8, 12, and 16 after DMM surgery or 4 and 8 weeks after sham surgery.
Drug administration. CNO (10 mg/kg in saline, intraperitoneally; Sigma-Aldrich) or vehicle (phosphate buffered saline [PBS] ) was administered to test the effect of neuronal inhibition on knee hyperalgesia or mechanical allodynia in Na V 1.8-Pdi mice (n 5 6-7 receiving vehicle, n 5 6-7 receiving CNO). At each time point, Na V 1.8-Pdi mice were tested for mechanical allodynia, allowed to rest for 2 days, and then tested for knee hyperalgesia. Between tests, treatment of mice was alternated between vehicle and CNO. A separate set of Na V 1.8-Pdi mice was tested for mechanical allodynia for the first time 16 weeks after DMM surgery (n 5 2 receiving vehicle, n 5 2 receiving CNO). Morphine (10 mg/kg in saline, SC) or vehicle (saline) was used to test reversibility of knee hyperalgesia (n 5 6 receiving morphine, n 5 6 receiving saline) or mechanical allodynia (n 5 4 receiving morphine, n 5 4 receiving saline) in the late stage of the DMM model (.12 weeks after surgery) in WT mice. Behaviors were tested 2 hours prior to injection and at the indicated times after injection by a blinded observer (SI or REM).
Histopathology of the knee. Sixteen weeks after sham surgery (n 5 11 WT mice, n 5 8 Na V 1.8-Pdi mice) or DMM surgery (n 5 10 WT mice, n 5 8 Na V 1.8-Pdi mice), histopathology of the knee was evaluated by Dr. Alison Bendele (Bolder BioPATH) based on modified Osteoarthritis Research Society International recommendations, as previously described (21, 39) . Joints were fixed in 10% formalin, decalcified, embedded in the frontal plane, sectioned (8 mm), and stained with toluidine blue (0.04% weight/volume). A section from the mid-joint (area of maximal damage [15] ) was used to score the medial femoral condyles and tibial plateaus for severity of cartilage degeneration. For each cartilage surface, scores were assigned individually to each of 3 zones (inner, middle, outer) on a scale of 0-5, with 5 representing the most damage (maximal summed score of 30 for femoral plus tibial cartilage degeneration). The largest osteophyte (medial tibia or femur) was measured using an ocular micrometer.
Immunofluorescence. For DRG analyses, naive Na V 1.8-Pdi male mice age .10 weeks (n 5 3) were used. For spinal cord analyses, naive Na V 1.8-Pdi (n 5 3) or Na V 1.8-TdTomato reporter (n 5 3) male and female mice age .10 weeks were used. Mice were anesthetized with ketamine and xylazine, killed, and perfused transcardially with PBS followed by 4% paraformaldehyde in PBS. The spinal column was dissected and postfixed in 4% paraformaldehyde overnight followed by cryopreservation in 30% sucrose in PBS. Individual L3-L5 DRGs or corresponding levels of the spinal cord were embedded in OCT compound (Tissue-Tek), frozen with dry ice, and cut into 12-mm (DRG) or 20-mm (spinal cord) sections. DRG sections were stained with the primary antibodies anti-Na V 1.8 (1:250 dilution, no. 75-166; Antibodies Incorporated) and anti-HA tag (1:250 dilution, no. 3724S; Cell Signaling Technology). Spinal cord sections were stained with anti-HA tag primary antibody and DAPI. A no-primary control was included to confirm specificity. Isotype-specific Alexa Fluor 405-, Alexa Fluor 488-, or Alexa Fluor 633-conjugated secondary antibodies (1:300 dilution; Invitrogen) were used. Images were captured using an Olympus FV10i confocal microscope, and images were adjusted using Olympus software to the brightness and contrast needed to reflect true colors.
Electrophysiology. Electrophysiologic recording from cultured DRG neurons isolated from naive Na V 1.8-TdTomatoPdi mice was performed using current clamp recordings employing patch electrodes with a resistance of 5-7 MV filled with 140 mM KCl, 0.5 mM EGTA, 5 mM HEPES, and 3 mM Mg-ATP, pH 7.3 (300 mOsm). Action potentials were evoked from (#25-mm diameter) Na V 1.8-positive neurons by using 700-msec depolarizing current (13, 23, or 33) injections from the resting membrane potential (approximately 255 mV) before or after application of CNO (2.5 mM). Control experiments were performed in the presence of pertussis toxin (1 mg/ml overnight).
Statistical analysis. For mechanical allodynia data, paw withdrawal thresholds were log-transformed prior to further analyses (40) . For mechanical allodynia and knee hyperalgesia analgesic time courses, a repeated-measures two-way analysis of variance (ANOVA) with Bonferroni post tests was used to compare mice treated with vehicle to mice treated with a particular drug at each time point. For knee hyperalgesia time courses in WT mice, a two-way ANOVA with Bonferroni post tests was used to compare responses of sham-operated and DMM-operated mice at each time point. For knee histopathology and electrophysiology, data were analyzed using the Mann-Whitney test. All analyses were carried out using GraphPad Prism software version 6.07 for Windows. Results are presented as the mean 6 SEM.
RESULTS
Na V 1.8-Pdi mice express functional DREADD receptors in Na V 1.8-expressing neurons. In order to ascertain that the DREADD receptor was expressed in Na V 1.8-expressing neurons in Na V 1.8-Pdi mice, immunofluorescence was performed in L3-L5 DRGs obtained from naive Na V 1.8-Pdi mice (n 5 3). As anticipated, nearly all (.90%) Na V 1.8-expressing neurons also stained for the DREADD receptor; no expression of the DREADD receptor was detected in non-Na V 1.8-expressing neurons (representative images shown in Figure 1A) . Colocalization of Na V 1.8 and Pdi was observed in small-to medium-diameter neurons (83-600 mm 2 ), consistent with the expected size of Na V 1.8-expressing neurons (35) . Interestingly, no DREADD expression was observed in the dorsal horn of the spinal cord ( Figure 1B) in the area where nociceptive DRG neurons, including Na V 1.8-expressing neurons, terminate ( Figure 1C ). This was presumably due to the lack of an axonal targeting motif in the DREADD used in these experiments (41) .
In order to confirm that the DREADD receptors were functional, patch-clamp electrophysiology was performed on cultured DRG cells from Na V 1.8-Pdi mice in which Na V 1.8-expressing cells were labeled with a Tomato reporter. Injection of current induced a series of action potentials in Na V 1.8-expressing DRG neurons (Figure 2A ). When neurons were incubated with CNO, action potential generation in Na V 1.8-expressing neurons was suppressed and the rheobase (the amount of current required to elicit an action potential) was increased, indicating that the DREADD receptors were functional ( Figures 2B and D) ; washing restored functionality of the neurons ( Figure 2C ). The effects of CNO were not observed if DREADD-expressing neurons were incubated overnight with pertussis toxin, indicating that the effects were mediated by DREADD-activated G i/o signaling ( Figures 2E-H) . Addition of CNO had no effect on the behavior of neurons cultured from WT, non-DREADDexpressing mice (data not shown).
Chemogenetic inhibition of Na V 1.8-expressing neurons reverses hind paw mechanical allodynia 8 weeks after DMM surgery, but not at later time points. We have previously demonstrated that WT mice develop mechanical allodynia by 4 weeks after DMM surgery and maintain this allodynia through 16 weeks (17, 21, 25) . Sham-operated mice develop initial mechanical allodynia that resolves by 8 weeks after surgery (17) . Likewise, Na V 1.8-Pdi mice displayed a baseline 50% withdrawal threshold of 0.64 6 0.05 gm prior to surgery, developed mechanical allodynia by 4 weeks after DMM surgery (50% withdrawal threshold of 0.03 6 0.004 gm), and maintained the same level of allodynia through week 16 (0-hour time points in Figure 3 ). Sham surgery induced some initial mechanical allodynia in Na V 1.8-Pdi mice 4 weeks after surgery (50% withdrawal threshold of 0.14 6 0.03 gm; n 5 5) (P 5 0.0001 versus before surgery) that resolved by 8 weeks after surgery (50% withdrawal threshold of 0.45 6 0.05 gm) (P 5 0.41 versus before surgery), as in WT mice. Histology performed 16 weeks after DMM surgery confirmed that Na V 1.8-Pdi mice developed similar levels of cartilage degeneration (P 5 0.50) (see Supplementary Figure 1A , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/ 10.1002/art.40118/abstract) and osteophytes (P 5 0.32) (Supplementary Figure 1B ) in the medial knee compartment compared to WT mice, while sham surgery did not cause joint damage (Supplementary Figure 1) .
Administering CNO to Na V 1.8-Pdi mice 4 weeks after DMM surgery partially inhibited mechanical allodynia for 1 hour (P 5 0.09) ( Figure 3A) . Administering CNO to mice 8 weeks after DMM surgery had a more robust effect on mechanical allodynia, inhibiting allodynia for 2 hours (P , 0.0001) ( Figure 3B) ; allodynia returned to predrug baseline levels by 4 hours after injection. In contrast, CNO had no effect on mechanical allodynia when administered to Na V 1.8-Pdi mice 12 or 16 weeks after DMM surgery ( Figures  3C and D) . CNO had no effect on mice not expressing Knee hyperalgesia following DMM surgery in WT mice. In addition to assessing the effects of neuronal inhibition on secondary mechanical allodynia of the hind paw, we sought to measure primary knee hyperalgesia using a previously validated PAM device (28, 29) , in order to apply a specific range of forces directly to the knee joint to determine a quantitative withdrawal threshold. Both sham and DMM surgeries induced knee hyperalgesia in WT mice, but DMM surgery caused more pronounced hyperalgesia 2-12 weeks after surgery ( Figure 4A ). Four weeks after surgery, knee hyperalgesia was reversible with SC injection of morphine (86 6 23% inhibition) ( Figure  4B ), suggesting that it is a pain-related behavior.
Chemogenetic inhibition of Na V 1.8-expressing neurons reverses knee hyperalgesia 4 weeks after DMM surgery, but not at later time points. Na V 1.8-Pdi mice and WT mice developed similar levels of knee hyperalgesia 4 through 16 weeks after DMM surgery (baseline time 0 in Figure 5 compared to Figure 4A ). Administering CNO to mice 4 weeks after DMM surgery inhibited knee hyperalgesia for 1 to 4 hours (65 6 9% inhibition at 1 hour) ( Figure 5A) ; by 24 hours after injection of CNO, knee hyperalgesia had returned to predrug baseline levels. Inhibition by CNO at this time point ( Figure 5A ) was comparable to that seen with morphine ( Figure 4B ). In contrast, injection of CNO had no effect 8 weeks (4 6 3% inhibition), 12 weeks (1 6 5% inhibition), or 16 weeks (21 6 1% inhibition) after DMM surgery ( Figures  5B-D) .
Effects of the centrally acting analgesic, morphine, on late-stage pain. In order to assess whether late-stage pain behaviors are susceptible to the effects of a centrally acting analgesic, we tested the effects of morphine, which is known to act centrally through the GPCR pathway. Although knee hyperalgesia was mild 12 weeks after surgery, morphine was still able to significantly reverse hyperalgesia (44 6 13% inhibition) in WT mice ( Figure 6A) . Similarly, mechanical allodynia was inhibited by morphine in WT mice tested between 13 and 16 weeks after DMM surgery ( Figure 6B ).
DISCUSSION
We used a chemogenetic approach employing DREADD receptors (Pdis) to examine whether activation of peripherally expressed inhibitory GPCRs was effective in reversing two pain-related behaviors, knee hyperalgesia and mechanical allodynia, at different stages after DMM surgery. We demonstrated that activation of Pdis expressed in the Na V 1.8-positive population of DRG neurons was effective in inhibiting the firing of these neurons, something that is shared with naturally occurring inhibitory GPCRs such as opioid receptors expressed in these cells. It is thought that inhibition of neuronal excitability and synaptic transmission constitutes the basis for the analgesic effects of drugs such as morphine, and so we imagined that this would also be true for appropriately expressed Pdis. Indeed, we might expect that activation of peripherally expressed Pdis in our experiments might actually be more effective than activation of peripherally expressed m-opioid receptors, as the Na V 1.8-expressing population of DRG neurons is more extensive than the population that expresses m-opioid receptors (42) .
The current study is also the first to show the pattern of knee hyperalgesia after surgery. Knee hyperalgesia developed as soon as 2 weeks after sham or DMM surgery and then slowly resolved over time. It was more pronounced after DMM surgery than after sham surgery, and this difference was still clear at week 12. The time course of resolution paralleled the resolution of synovitis in this model (16) and was similar to the knee hyperalgesia and synovitis pattern reported in the antigen-induced arthritis model (29) . Hence, while early OA changes in the joint may contribute to the establishment of knee hyperalgesia after DMM surgery, it should be considered that this assay failed to demonstrate differences in hyperalgesia between DMM-operated and sham-operated animals at week 16; thus, knee hyperalgesia may indicate postsurgical or postinjury pain more than OA-related pain. The finding that chemogenetic inhibition of Na V 1.8-expressing neurons blocks knee hyperalgesia 4 weeks after surgery might, in fact, suggest analgesic strategies for early post-joint surgery pain or postinjury pain, even though the relevance to OA remains unclear and further work needs to be done to establish which pathologic features contribute to knee hyperalgesia.
Chemogenetic inhibition of Na V 1.8-expressing sensory neurons blocked knee hyperalgesia and secondary mechanical allodynia at early stages of experimental OA, but DREADD activation was no longer effective during the later stages (.8 weeks after DMM surgery). In contrast, morphine, a drug that normally activates inhibitory GPCRs expressed in both the peripheral and central components of the pain pathway, was still effective at the later stage.
These results support work performed in other experimental OA models, which have noted a timedependent effect of pharmacologic modulation of pain. For example, in the rat monoiodoacetate model, NSAIDs are effective in reversing weight-bearing deficits, paw hyperalgesia, and knee hyperalgesia in the first 2 weeks after induction (43) (44) (45) , but by day 21, only drugs which are associated with powerful central analgesic mechanisms, such as morphine and gabapentin, are effective (44) (45) (46) (47) . Similarly, in the mouse partial meniscectomy model, an NSAID was effective in reversing paw and knee hyperalgesia in an early stage (day 7) but not in a late stage (day 42), while morphine could reverse both behaviors in the late phase (27) . Together with the results presented herein, these data suggest that therapies targeted at the peripheral nervous system alone may no longer be sufficient for analgesia in the late stage of OA. This is not because peripheral mechanisms of pain inhibition are ineffective in all types of pain. Sole activation of peripherally expressed m-opioid receptors using either genetic techniques or opioids that do not enter the CNS can inhibit pain in some circumstances (11, 48) . Similarly, activation of Pdis uniquely expressed in the Na V 1.8-expressing DRG population, as described in the current report, is effective in blocking pain in other situations such as painful diabetic neuropathy (Menichella DM, Miller RJ: unpublished observations). Nevertheless, our data do indicate that there must be changes in the way that the pathways signaling pain are organized in later stages of OA.
In the current study, we used Na V 1.8 as a marker to target a specific population of sensory neurons. Two studies tested the efficacy of targeting the ion channel itself by using a small-molecule inhibitor of Na V 1.8, A-803467, in the rat monoiodoacetate model (36, 37) . Both studies focused on day 14, which is in the NSAID-sensitive phase of the model. This inhibitor was able to reduce the mechanosensitivity of joint afferent fibers during noxious rotation of the joint (36), reverse weight bearing, and mechanical allodynia (36) , and it could block spinal neuron responses to mechanical and thermal stimuli (37) . These results suggest that at least some of the observed effects may in fact be mediated by Na V 1.8 itself. Future work will be directed toward testing this hypothesis.
There are several potential explanations for our findings indicating that blocking the firing of action potentials in peripheral Na V 1.8-positive sensory neurons is not sufficient to reverse pain-related behaviors in the late stage of the DMM model. GPCRs, such as those for opioids and cannabinoids, expressed by DRG neurons inhibit the transmission of information into the spinal cord by several mechanisms. Receptors expressed in the DRG can inhibit spike firing, while those on terminals in the dorsal horn reduce transmitter release through inhibition of voltage-dependent calcium influx into nerve terminals (49) . It is possible that this latter mechanism becomes more important during later phases of the disease, and the lack of DREADD receptors in the dorsal horn is reflected by their inability to affect pain at later time points.
While it is also possible that the lack of efficacy in the late stage is due to the development of tolerance, the development of tolerance in this case is unlikely for the following reasons. We administered CNO in 1-month intervals, and the effect of chronic CNO administration has been shown to wash out within 48 hours (50) . In addition, we tested a separate set of mice at only the 116-week time point and found that CNO still had no effect on mechanical allodynia (see Supplementary Figure 3 , http://onlinelibrary. wiley.com/doi/10.1002/art.40118/abstract). Our results can also be compared with those of another recent study that used a non-drug-based strategy: optogenetic silencing of Na V 1.8-expressing nociceptors was achieved by using a light-activated inhibitory proton pump to study the effects on pain in a nerve injury mouse model (51) . Although-in contrast to the current approach-expression of the pump was demonstrated both in the DRG cell bodies as well as in the axons in the periphery and the dorsal horn, the authors reported findings very similar to our current results: inhibiting Na V 1.8-positive sensory neurons in the spared nerve injury neuropathic pain model reversed mechanical allodynia of the hind paw in the early phase (3-4 weeks after surgery) but not in the late phase (6-9 weeks after surgery) (51).
These results suggest that expression of the DREADD receptor in the axons might not improve inhibition in the late phase of experimental OA. It is also possible that during the later stages of this experimental OA model, central sensitization may contribute to the observed pain-related behaviors. Little is known regarding central sensitization in experimental mouse models of OA, but our results suggest that it will be important to investigate how central pathways contribute to chronic OA pain. There is ample clinical evidence to support the notion that OA pain is generated and maintained through continuous nociceptive input from the damaged joint, which is underscored by the fact that the majority of patients are free of pain after total knee replacement (52) . Clearly, it is an important limitation of the current study that chemogenetic inhibition of Na V 1.8-expressing neurons was only transient. The effects of extended administration of CNO-early, late, or continuous-will be tested in future studies.
Another possibility is that the lack of efficacy in the late phase of the DMM model may indicate phenotypic changes in the non-Na V 1.8-expressing sensory neuron population (a subset of Ad-fibers and Ab-fibers). Normally, myelinated Ab-fibers convey low-threshold stimuli as light touch. Clinical studies have suggested that, under pathologic conditions, neuronal plasticity results in these Ab-fibers now interpreting light touch as being painful (mechanical allodynia) (53) (54) (55) . Recently, targeted silencing of Ab-fibers was shown to reduce persistent mechanical allodynia associated with neuropathic pain models (56) , but the exact sensory neuron subsets that mediate mechanical allodynia associated with different types of neurons remain to be fully identified (57) . Therefore, it is possible that the behaviors related to mechanical sensitivity tested in the present study may involve a mixture of Na V 1.8-and non-Na V 1.8-expressing sensory neurons, and the roles of each population may change over the course of the model. This will be a focus of future research.
A limitation of the studies reported here is that we focused on two evoked behaviors, mechanical hyperalgesia of the knee and mechanical allodynia of the hind paw. In order to assess effects of silencing Na V 1.8-expressing neurons on spontaneous behaviors, such as locomotion deficits, future work will focus on delivering CNO in a chronic manner. Chronic administration of CNO will also allow us to determine whether long-term suppression of Na V 1.8-expressing cells is sufficient to prevent the onset of chronic pain in this model.
In conclusion, we have demonstrated that using the inhibitory G i/o protein pathway to transiently inhibit the majority of sensory neurons is only able to inhibit knee hyperalgesia and mechanical allodynia of the hind paw in the early stage of the DMM mouse model of OA. Importantly, our results set limits on the mechanisms of any new drugs designed to treat OA pain that target inhibitory GPCRs using the same G i/o protein pathway. Our data suggest that activation of inhibitory GPCRs solely expressed in peripheral sensory neurons may not be effective in treating chronic OA pain, although the effects of long-term inhibition need to be studied. This work may lead to a better understanding of which analgesics are effective in different stages of OA, and may also lead to novel therapeutics targeting specific subsets of neurons in different stages of disease.
